Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamikibart in uveitic macular edema
NCT05642312Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of vamikibart in uveitic macular edema (UME), sponsored by Roche. Started Jan 2023; status: completed.
02
Drugs
vamikibart
03
Conditions
uveitic macular edema (UME)
Beyond the preview
Go deeper on NCT05642312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642312.